Table 1: Quality Indicators by Site, Zone and Province, individuals ages 50-69, Screen Years 2016_2017

Number of Exams NA 2855 4249 5919 37256 6658 4357 10142 5857 5184 17761 13069 14391 37256 82477 Number of Exams NA 160 169 247 1394 345 164 464 168 174 766 492 633 1394 3255 Number of Screen Detected RNA 17 18 35 218 22 25 45 33 34 91 75 63 218 447 Reterior Reteri	Indicator	Target	AM	AN	BR	Central [△]	KE	NG	SY	TR	YΑ	Western	Northern	Eastern	Central	Nova Scotia
Number of 1st Screen NA	Number of Fueres	NIA	2055	4240	F010		CCEO	4257	10143	F0F7	F104					02477
Number of Screen Detected Cancers Name 17 18 35 218 22 25 45 33 34 91 75 63 218 447												<u> </u>				
Coverage Participation Rate, 30 month* 2 70% 52.3% 57.0% 54.6% 58.0% 49.5% 55.2% 46.5% 48.6% 51.4% 51.6% 51.5% 49.2% 58.0% 53.8% Retention Rate*		INA	100	109	247	1394	343	104	404	100	1/4	700	492	033	1554	3203
Participation Rate, 30 month* 2 70% 52.3% 57.0% 54.6% 58.0% 49.5% 55.2% 46.5% 48.6% 51.4% 51.6% 51.5% 49.2% 58.0% 53.8%		NA	17	18	35	218	22	25	45	33	34	91	75	63	218	447
Retention Rate* Initial \$\geqrightarrow{2} \sqrt{5} \text{37.1} \text{24.5} \text{40.5} \text{36.4} \text{32.3} \text{40.2} \text{33.3} \text{27.3} \text{40.5} \text{36.3} \text{36.2} \text{36.3} \text{36.3} \text{36.3} \text{36.3} \text{36.3} \text{36.3} \text{36.2} \text{36.3} \text{36.3} \text{36.2} \text{36.3} \text{36.2} \text{36.3} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.2} \text{36.3} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.2} \text{36.2} \text{36.3} \text{36.3} \qq \qq \qq \qq \qq \qq \qq \qq \qq \qq \qq \qq \																
Initial 2 75% 37.1% 24.5% 40.5% 36.4% 32.3% 40.2% 33.3% 27.3% 40.5% 36.3% 34.2% 35.8% 37.0% 36.0% Subsequent 2 90% 80.0% 79.0% 82.2% 79.5% 76.6% 84.9% 65.5% 76.7% 81.3% 78.3% 80.2% 78.3% 79.2% 78.9%	Participation Rate, 30 month*	≥ 70%	52.3%	57.0%	54.6%	58.0%	49.5%	55.2%	46.5%	48.6%	51.4%	51.6%	51.5%	49.2%	58.0%	53.8%
Subsequent ≥ 90% 80.0% 79.0% 82.2% 79.5% 76.6% 84.9% 65.5% 76.7% 81.3% 78.3% 80.2% 78.3% 79.2% 78.9% 7	Retention Rate [‡]															
Pollow-Up Abnormal Call Rate Initial < 10% 16.9% 21.9% 17.8% 11.1% 13.3% 19.5% 16.8% 28.6% 16.7% 15.5% 21.7% 18.2% 11.1% 14.4% Subsequent < 5% 7.2% 7.8% 6.0% 4.5% 4.7% 7.9% 5.2% 9.0% 6.2% 5.6% 8.3% 6.0% 4.5% 5.6%	Initial	≥ 75%	37.1%	24.5%	40.5%	36.4%	32.3%	40.2%	33.3%	27.3%	40.5%	36.3%	34.2%	35.8%	37.0%	36.0%
Abnormal Call Rate Initial	Subsequent	≥ 90%	80.0%	79.0%	82.2%	79.5%	76.6%	84.9%	65.5%	76.7%	81.3%	78.3%	80.2%	78.3%	79.2%	78.9%
Initial < 10% 16.9% 21.9% 17.8% 11.1% 13.3% 19.5% 16.8% 28.6% 16.7% 15.5% 21.7% 18.2% 11.1% 14.4% Subsequent < 5% 7.2% 7.8% 6.0% 4.5% 4.5% 4.7% 7.9% 5.2% 9.0% 6.2% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 6.0% 4.5% 5.6% 5.6% 6.0% 4.5% 5.6% 5.6% 6.0% 4.5% 5.6% 5.6% 6.0% 4.5% 5.6% 6.0% 4.5% 5.6% 6.0% 4.5% 5.6% 6.0% 6.2% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 6.0% 6.2% 5.6% 6.0% 4.5% 5.6% 6.0% 6.2% 6.2% 5.6% 6.0% 6.2% 6.2% 5.6% 6.0% 6.2% 6.2% 6.0% 6.2% 6.2% 6.0% 6.2% 6.2% 6.2% 6.2% 6.2% 6.2% 6.2% 6.2	Follow-Up															
Subsequent < 5% 7.2% 7.8% 6.0% 4.5% 4.7% 7.9% 5.2% 9.0% 9.0% 6.2% 5.6% 8.3% 6.0% 4.5% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5	Abnormal Call Rate															
Diagnostic Interval a % notified within 2 weeks of screen ≥ 90% 90.3% 97.5% 94.8% 98.2% 98.2% 98.8% 95.4% 99.3% 96.9% 94.0% 93.5% 97.3% 98.5% 96.5%	Initial	< 10%	16.9%	21.9%	17.8%	11.1%	13.3%	19.5%	16.8%	28.6%	16.7%	15.5%	21.7%	18.2%	11.1%	14.4%
a] % notified within 2 weeks of screen ≥ 90% 90.3% 97.5% 94.8% 98.2% 98.2% 98.8% 95.4% 99.3% 96.9% 94.0% 93.5% 97.3% 98.5% 96.5% b) Time from abnormal screen to definitive diagnosts Owith tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 5 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 5 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 7 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Power than 1 tissue biopsy (% diagnosed within 5 weeks) Owith tissue biopsy (% diagnosed within 7 weeks) Owith	Subsequent	< 5%	7.2%	7.8%	6.0%	4.5%	4.7%	7.9%	5.2%	9.0%	6.2%	5.6%	8.3%	6.0%	4.5%	5.6%
of screen ≥ 90% 90.3% 97.5% 94.8% 98.2% 98.2% 98.2% 98.8% 95.4% 99.3% 95.9% 94.0% 93.5% 97.3% 98.5% 96.5% b) Time from abnormal screen to definitive diagnosis	Diagnostic Interval															
b] Time from abnormal screen to definitive diagnosis	a] % notified within 2 weeks	> 00%	90.3%	97.5%	94.8%	98.2%	98.2%	98.8%	95.4%	99.3%	96.9%	94.0%	93.5%	97.3%	98.5%	96.5%
Owithout tissue biopsy (% diagnosed within 5 weeks) ≥ 90% 68.4% 80.5% 65.0% 86.7% 90.4% 92.7% 71.4% 83.0% 32.4% 66.3% 82.9% 75.1% 86.7% 78.4% Owith tissue biopsy (% diagnosed within 7 weeks) ≥ 90% 61.0% 70.0% 73.4% 78.5% 70.8% 88.8% 74.8% 64.1% 25.0% 52.9% 71.4% 73.2% 78.5% 71.0% Quality of Screening Benign: Malignant Core Biopsy Ratio a] Initial None Small Cell Undefined Small Cell Undefined Small Cell Undefined Small Cell 6.00:1 Small Cell Small Cell Small Cell 3.58:1 4.96:1 <							30.275									
Section State S		to definit	ive diagno	sis												
diagnosed within 7 weeks) ≥ 90% 61.0% 70.0% 73.4% 78.5% 70.8% 88.8% 74.8% 64.1% 25.0% 52.9% 71.4% 73.2% 78.5% 71.0% Quality of Screening Benign: Malignant Core Biopsy Ratio a] Initial None Small Cell Undefined Small Cell Undefined Small Cell Undefined Small Cell 6.00 : 1 Small Cell Small Cell 3.58 : 1 4.96 : 1 b] Subsequent None 2.09 : 1 1 : 1 2.05 : 1 2.37 : 1 1.75 : 1 2 : 1 1.07 : 1 2.71 : 1 2.09 : 1 1 : 98 : 1 2.37 : 1 2.08 : 1 Benign: Malignant Open Surgical Biopsy Ratio a] Initial ≤ 1 : 1 Small Cell Undefined Small Cell Small Cell Small Cell Small Cell Small Cell Small Cell 0.00 : 1 Small Cell b] Subsequent ≤ 1 : 1 Small Cell 0.23 : 1 0.09 : 1 0 : 1 Small Cell 0.15 : 1 0.16 : 1 Small Cell 0.10 : 1 0.10 : 1 0.11 : 1 0.12 : 1 0.09 : 1 0.10 : 1 0.10 :		≥ 90%	68.4%	80.5%	65.0%	86.7%	90.4%	92.7%	71.4%	83.0%	32.4%	66.3%	82.9%	75.1%	86.7%	78.4%
Quality of Screening Benign: Malignant Core Biopsy Ratio a] Initial None Small Cell Undefined Small Cell 3.58:1 Small Cell Undefined Small Cell Undefined Small Cell 6.00:1 Small Cell Small Cell 3.58:1 4.96:1 b] Subsequent None 2.09:1 1:1 2.05:1 2.37:1 1.75:1 2:1 1.07:1 2.71:1 2.09:1 1.98:1 2.34:1 1.05:1 2.37:1 2.08:1 Benign: Malignant Open Surgical Biopsy Ratio a] Initial ≤ 1:1 Small Cell Undefined Small Cell 0:1 Small Cell Undefined Small Cell O.10:1 0.10:1	. , ,	≥ 90%	61.0%	70.0%	73.4%	78.5%	70.8%	88.8%	74.8%	64.1%	25.0%	52.9%	71.4%	73.2%	78.5%	71.0%
Benign: Malignant Core Biopsy Ratio a] Initial None Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Small Cell Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Small Cell Undefined Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Undefined Small Cell Small Cell Undefined Smal																
a] Initial None Small Cell Undefined Small Cell Sma		Ratio														
Benign : Malignant Open Surgical Biopsy Ratio a Initial ≤ 1 : 1 Small Cell Undefined Small Cell 0 : 1 Small Cell Undefined Small Cell O.00 : 1 Small Cell Small Cell O.10 : 1 O.12 : 1 O.12 : 1 O.10 : 1			Small Cell	Undefined	Small Cell	3.58 : 1	Small Cell	Undefined	Small Cell	Undefined	Small Cell	6.00 : 1	Small Cell	Small Cell	3.58 : 1	4.96 : 1
Benign : Malignant Open Surgical Biopsy Ratio a Initial ≤ 1 : 1 Small Cell Undefined Small Cell 0 : 1 Small Cell Undefined Small Cell O.00 : 1 Small Cell Small Cell O.10 : 1 O.12 : 1 O.12 : 1 O.10 : 1	hl Subsequent	None	2.09 · 1	1 · 1	2.05 · 1	2 27 · 1	1 75 · 1	2 · 1	1 07 · 1	2 71 · 1	2 00: 1	1 00 · 1	2 2/1 · 1	1 05 · 1	2 27 · 1	2.08 · 1
a] Initial ≤1:1 Small Cell Undefined Small Cell 0:1 Small Cell Undefined Small Cell 0.00:1 Small Cell 0.15:1 0.16:1 Small Cell 0.10:1 0.11:1 0.12:1 0.09:1 0.10:1 PPV a] Initial ≥ 5% Small Cell 0.0% Small Cell 9.7% Small Cell 0.0% Small Cell Small Cel				1.1	2.03 . 1	2.57 . 1	1.73.1	2.1	1.07 . 1	2.71.1	2.03. 1	1.36 . 1	2.34 . 1	1.05 . 1	2.37 . 1	2.08 . 1
PPV a] Initial ≥ 5% Small Cell 0.0% Small Cell 9.7% Small Cell 0.0% Small Cell 9.7% 5.6%		, ,		Undefined	Small Cell	0:1	Small Cell	Undefined	Small Cell	0.00:1	Small Cell					
a] Initial ≥ 5% Small Cell 0.0% Small Cell 9.7% Small Cell 0.0% Small Cell S	b] Subsequent	≤1:1	Small Cell	Small Cell	0.23 : 1	0.09:1	0:1	Small Cell	0.15 : 1	0. 16 : 1	Small Cell	0.10:1	0.11:1	0.12 : 1	0.09:1	0.10:1
	PPV															
b] Subsequent ≥ 6% 8.3% 5.7% 9.0% 12.7% 6.8% 7.5% 8.2% 6.0% 10.3% 8.7% 6.9% 7.2% 12.7% 9.4%	a] Initial	≥ 5%	Small Cell	0.0%	Small Cell	9.7%	Small Cell	0.0%	Small Cell	Small Cell	Small Cell	6.7%	Small Cell	Small Cell	9.7%	5.6%
	b] Subsequent	≥ 6%	8.3%	5.7%	9.0%	12.7%	6.8%	7.5%	8.2%	6.0%	10.3%	8.7%	6.9%	7.2%	12.7%	9.4%

Indicator	Target	АМ	AN	BR	C entral [△]	KE	NG	SY	TR	YA	Western Zone 1	Northern Zone 2	Eastern Zone 3	Central Zone 4	Nova Scotia
Detection															
In Situ Cancer Detection Rate															
a] Initial	None	0.00	0.00	0.00	0.00	0.00	0.00	0.00	Small Cell	0.00	0.00	Small Cell	0.00	0.00	Small Cell
b] Subsequent	None	Small Cell	Small Cell	Small Cell	1.00	Small Cell	Small Cell	Small Cell	Small Cell	1.20	0.82	0.64	0.36	1.00	0.86
Cancer Detection Rate															
	>5 per														
a] Initial	1,000	Small Cell	0.0	Small Cell	10.8	Small Cell	0.0	Small Cell	Small Cell	Small Cell	10.4	Small Cell	Small Cell	10.8	8.1
	screens														
	> 3 per														
b] Subsequent	1,000	5.9	4.4	5.5	5.7	3.2	6.0	4.2	5.4	6.4	4.9	5.7	4.3	5.7	5.3
	screens														
Disease Extent at Diagnosis															
Screen Detected Invasive Turmo	our Size														
<= 10mm †	>25% †	Small Cell	50.0%	26.1%	37.8%	31.8%	45.0%	60.0%	53.3%	34.8%	30.9%	43.8%	55.0%	37.8%	39.7%
<= 15 mm	>50%	42.9%	70.0%	47.8%	69.2%	77.3%	60.0%	70.0%	60.0%	47.8%	57.4%	56.3%	70.0%	69.2%	64.3%
Proportion of Node Negative															
Screen Detected Invasive	>70%	71.4%	70.0%	69.6%	82.0%	81.8%	85.0%	80.0%	63.3%	82.6%	77.9%	71.9%	75.0%	82.0%	77.1%
Cancer															

Small Cell: when cell size is between 1 and 4, it is suppressed to prevent potential identification of patients, especially in smaller communities/sites.

The benign to malignant open surgical biopsy ratio is undefined when the denominator is zero.

[△] This includes three screening locations: Cobequid, Dartmouth and Halifax

The benign to malignant core biopsy ratio is undefined when the denominator is zero.

^{*} Participation Rate is presented for a 30 month period ending December 31 2017

[‡] Retention Rate is presented for women ages 50-67 who had a screen in 2015, and who were re-screened within 30 months of their previous screen

[†] No longer monitored at the national level, but NSBSP continues to monitor

 Table 2: Quality Indicators by Age Group, Screen Years 2016_2017

Indicator	Target (Ages 50-69)	40 to 49	50 to 59	60 to 69	70+
Number of Exams	NA	29377	42553	40957	13852
Number of 1st Screens	NA	7023	2375	1318	316
Number of Screen Detected Cancers	NA	74	173	276	156
Coverage					
Participation Rate, 30 month*	≥ 70%	40.2%	52.5%	59.1%	20.1%
Retention Rate [‡]					
Initial	≥ 75%	58.9%	33.9%	36.9%	17.4%
Subsequent	≥ 90%	85.0%	77.7%	74.6%	57.1%
Follow-Up					
Abnormal Call Rate					
Initial	< 10%	14.0%	15.1%	13.1%	13.3%
Subsequent	< 5%	10.6%	6.4%	6.7%	7.4%
Diagnostic Interval - Time from abnormal screen to definitive	diagnosis				
without tissue biopsy (% diagnosed within 5 weeks)	≥ 90%	79.0%	78.6%	78.3%	73.9%
♦ with tissue biopsy (% diagnosed within 7 weeks)	≥ 90%	66.6%	70.2%	71.7%	70.5%
Quality of Screening	_				
Benign : Malignant Core Biopsy Ratio					
a] Initial	None	9.12 : 1	5.82 : 1	2.76:1	1.57 : 1
b] Subsequent	None	4.47 : 1	2.30 : 1	1.59 : 1	1.19 : 1
Benign: Malignant Open Surgical Biopsy Ratio					
a] Initial	≤1:1	0.35 : 1	small cell	small cell	0.00:1
b] Subsequent	≤1:1	0.29 : 1	0.15 : 1	0.07 : 1	0.04:1
PPV					
a] Initial	≥ 5%	2.3%	4.2%	8.7%	19.0%
b] Subsequent	≥ 6%	3.1%	7.2%	11.5%	17.6%
Detection					
In Situ Cancer Detection Rate					
a] Initial	None	0.71	0.00	small cell	small cell
b] Subsequent	None	0.45	0.73	1.30	2.11

Indicator	Target (Ages 50-69)	40 to 49	50 to 59	60 to 69	70+
Invasive Cancer Detection Rate					
a] Initial	>5 per 1,000 screens	3.3	6.3	11.4	25.3
b] Subsequent	> 3 per 1,000 screens	3.3	4.6	7.7	13.0
Disease Extent at Diagnosis					
Screen Detected Invasive Turmour Size					
<= 10mm †	>25% †	29.0%	40.4%	39.3%	42.0%
<= 15 mm	>50%	50.0%	65.8%	63.3%	70.2%
Proportion of Node Negative Screen Detected Invasive Cancer	>70%	64.5%	75.3%	78.2%	84.0%

Small Cell: when cell size is between 1 and 4, it is suppressed to prevent potential identification of patients, especially in smaller communities/sites.

^{*} Participation Rate is presented for a 30 month period ending December 31 2017

[‡]Retention Rate is presented for women who had a screen in 2015, and who were re-screened within 30 months of their previous screen

[†] No longer monitored at the national level, but NSBSP continues to monitor

Table 3: Quality Indicators Time Trend, 2013 to 2017

Indicator	Target	2013	2014	2015	2016	2017
Number of Exams	NA	41431	41817	41671	43544	39966
Number of 1st Screens	NA	1943	2482	2001	2028	1665
Number of Screen Detected Cancers	NA	216	273	271	222	227
Coverage						
Participation Rate, 30 month*	≥ 70%	55.5%	55.4%	56.1%	54.6%	53.8%
Retention Rate [‡]						
Initial	≥ 75%	43.9%	39.7%	36.7%	44.4%	36.0%
Subsequent	≥ 90%	78.2%	77.8%	77.0%	81.1%	78.9%
Follow-Up						
Abnormal Call Rate						
Initial	< 10%	16.3%	14.8%	14.7%	13.7%	15.3%
Subsequent	< 5%	5.4%	5.0%	5.2%	5.3%	5.8%
Diagnostic Interval - Time from abnormal screen to definitive diagr	nosis					
♦ without tissue biopsy (% diagnosed within 5 weeks)	≥ 90%	76.5%	78.6%	80.6%	83.9%	72.9%
♦ with tissue biopsy (% diagnosed within 7 weeks)	≥ 90%	67.9%	62.6%	70.7%	75.9%	65.8%
Quality of Screening						
Benign: Malignant Core Biopsy Ratio						
a] Initial	None	4.21:1	2.90:1	1.94 : 1	4.15 : 1	4.50 : 1
b] Subsequent	None	2.29 : 1	1.80 : 1	1.66 : 1	2.03 : 1	1.71 : 1
Benign: Malignant Open Surgical Biopsy Ratio						
a] Initial	≤ 1:1	0.1:1	0.1:1	0.2:1	0.2 : 1	small cell
b] Subsequent	≤ 1:1	0.2 : 1	0.1:1	0.1:1	0.1:1	0.06 : 1
PPV						
PPV a] Initial	≥ 5%	8.8%	8.7%	11.5%	6.8%	4.3%
	≥ 5% ≥ 6%	8.8% 8.9%	8.7% 12.4%	11.5% 11.7%	6.8% 9.4%	4.3% 9.7%
a] Initial						
a] Initial b] Subsequent						
a] Initial b] Subsequent Detection						

Indicator	Target	2013	2014	2015	2016	2017
Invasive Cancer Detection Rate						
a] Initial	>5 per 1,000 screens	11.3	10.9	15.5	9.4	7.2
b] Subsequent	> 3 per 1,000 screens	3.9	5.0	4.8	4.9	5.7
Disease Extent at Diagnosis						
Screen Detected Invasive Turmour Size						
<= 10mm †	>25% †	34.0%	42.6%	36.3%	37.3%	41.9%
<= 15 mm	>50%	63.2%	64.9%	62.1%	60.4%	67.2%
Proportion of Node Negative Screen Detected Invasive Cancer	>70%	79.5%	83.6%	81.4%	77.8%	80.6%

Small Cell: when cell size is between 1 and 4, it is suppressed to prevent potential identification of patients, especially in smaller communities/sites.

^{*} Participation Rate is presented for a 30 month period ending December 31 2017

[‡]Retention Rate is presented for women ages 50-67 who had a screen in 2015, and who were re-screened within 30 months of their previous screen

[†] No longer monitored at the national level, but NSBSP continues to monitor